A5075324403- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- Cell death mechanisms and regulation
- Lung Cancer Research Studies
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Nutrition and Health in Aging
- Sexual Differentiation and Disorders
- Urinary and Genital Oncology Studies
- Infective Endocarditis Diagnosis and Management
- Brain Metastases and Treatment
- Cancer-related molecular mechanisms research
- Infectious Aortic and Vascular Conditions
- Immunodeficiency and Autoimmune Disorders
- Nonmelanoma Skin Cancer Studies
- Cervical Cancer and HPV Research
- Radiopharmaceutical Chemistry and Applications
- Microbial metabolism and enzyme function
- Venous Thromboembolism Diagnosis and Management
Fox Chase Cancer Center
2020-2024
Medical University of South Carolina
2018-2020
MUSC Hollings Cancer Center
2019
SUNY Upstate Medical University
2014-2016
Upstate University Hospital
2016
State University of New York
2015
Wayne State University
2007
Primary or acquired resistance to cetuximab, an antiepidermal growth factor receptor monoclonal antibody (mAb), minimizes its utility in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Aberrant hepatocyte factor/cMet pathway activation is established mechanism. Dual targeting may overcome resistance.This multicenter, randomized, noncomparative phase II study evaluated ficlatuzumab, antihepatocyte mAb, with without cetuximab HNSCC. The primary end point was median...
Abstract Plasmablastic lymphoma (PBL) is a rare entity, commonly associated with immunosuppressed states such as human immunodeficiency virus (HIV) infection or solid organ transplant. The clinical course characterized by high relapse rates and poor prognosis, leading some clinicians to recommend aggressive frontline therapy. However, specific review of limited stage (LS) PBL patients not available evaluate outcomes justify treatment recommendations. We performed retrospective LS cases...
There is a paucity of data regarding outcomes and response to standard therapy in patients with limited-stage (LS) agressive B-cell lymphoma (LS-ABCL) who harbor MYC rearrangement (MYC-R) or without BCL2 and/or BCL6 rearrangements. We conducted multicenter retrospective study MYC-R LS-ABCL received either rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), more intensive immunochemotherapy (IIC) plus minus consolidative involved-field radiation (IFRT). One hundred...
As the number of indicated malignancies for which immune checkpoint inhibitor therapy such as pembrolizumab grows descriptions associated immune-related adverse events (irAEs) increases well. On rare occasions immunotherapy can lead to development Hemophagocytic Lymphohistiocytosis (HLH) is a potentially lethal inflammatory disorder characterized by histiocyte activation and cytokine storm. At this time no cases HLH developing in head neck squamous cell carcinoma (HNSCC) patients receiving...
Background Salvage immunochemotherapy followed by high‐dose chemotherapy and autologous stem cell transplantation is the standard‐of‐care second‐line treatment for patients with relapsed/refractory diffuse large B‐cell lymphoma after first‐line R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Outcomes receipt of in aggressive lymphomas who relapse or are refractory to intensive regimens (etoposide, prednisone, rituximab [R‐EPOCH], rituximab, hyperfractionated...
Management of hypopharynx cancer is often extrapolated from larynx cancer. This report analyses treatment patterns and survival limited to using the National Cancer Database (NCDB).There are 9314 patients diagnosed with between 2004 2016. The association modality was analyzed Kaplan-Meier curves multivariable Cox regression.Five-year overall ranged 45% for stage I 21% IVB. Treatment did not influence in I/II. For III/IV, chemoradiation surgery + adjuvant therapy were equivalent. Surgery...
6015 Background: Cetuximab (C), an anti-EGFR monoclonal antibody (mAb), is approved for advanced HNSCC but benefits a minority. Crosstalk between the EGFR and hepatocyte growth factor (HGF)/cMet pathways known resistance mechanism. HGF also immunosuppressive within tumor microenvironment. A Phase I study confirmed safety of C ficlatuzumab (F), IgG1 anti-HGF mAb, with preliminary efficacy biomarker data suggesting that dual pathway inhibition may overcome tumor-intrinsic or immune cetuximab...
6049 Background: Better outcomes are needed for patients (pts) with locoregional inoperable recurrence or second primary HNSCC after prior radiation therapy. Methods: We conducted a phase II single arm trial of hyperfractionated reirradiation (ReRT, 1.2 Gy BID total 60Gy to gross disease + margin without elective nodal radiation) plus pembrolizumab (P) (200mg q3 weeks starting day 1 ReRT). P was continued until confirmed CR if no CR, progression up 24 months. All pts underwent 3 month post...
Copyright © by 2014 the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
e24103 Background: Malnutrition and poor dietary habits are associated with worse outcomes decreased quality of life (QOL) in patients HNC. Given the lack standardized assessment diet survivors HNC but concern for long term malnutrition risk, we piloted a recently developed computerized FFQ that provides individualized feedback (Vioscreen) We sought to assess its feasibility acceptability explore associations between quality, QOL, patient/treatment characteristics. Methods: recruited who had...
TPS6594 Background: Patients with pan-refractory R/M HNSCC, clinical resistance to cytotoxic therapy, anti-EGFR molecular targeting, and immunotherapy, have poor survival. An established tumor-intrinsic mechanism cetuximab, an IgG1 monoclonal antibody (mAb), is activation of the hepatocyte growth factor (HGF)/cMet pathway, which converges EGFR network at both PI3K/Akt MAPK nodes allowing for reciprocal compensation. Moreover, over-expression HGF in tumor microenvironment immunosuppressive....
e18615 Background: Multidisciplinary tumor boards are widely accepted as vehicles for improving patient outcomes in Head and Neck Cancer (HNC). Little work describes their structure practices. The purpose of this study is to better understand the international practice patterns multidisciplinary HNC boards. Methods: A cross-sectional survey on head neck cancer board was developed by a panel six experts distributed internationally providers. interrogated attendance, participation, operation,...